



CT License: CL-0644
CLIA: # 07D1036625

LABORATORY OF PERSONALIZED HEALTH
Division of Genomas Inc.
67 Jefferson Street · Hartford, CT 06106
Tel: (860) 545.4574 Fax: (860) 545.4598
www.genomas.net/LPH

HILomet WARFARIN
CYP2C9 AND VKORC1 DNA TYPING REPORT

Patient Name: _____ Patient ID: _____ LPH ID: _____

Patient Date of Birth: _____ Date of specimen receipt into laboratory: _____

Name of Physician/Authorized person requesting test: _____

CYP2C9 ALLELES	CARRIER STATUS	METABOLIZER STATUS
<input type="checkbox"/> WT	<input type="checkbox"/> Normal	<input type="checkbox"/> Functional
<input type="checkbox"/> *2	<input type="checkbox"/> Carrier	<input type="checkbox"/> Deficient
<input type="checkbox"/> *3	<input type="checkbox"/> Double Carrier	<input type="checkbox"/> Poor
<input type="checkbox"/> *4		
<input type="checkbox"/> *5		
<input type="checkbox"/> *6		
VKORC1 ALLELES	CARRIER STATUS	SENSITIVITY STATUS
<input type="checkbox"/> WT	<input type="checkbox"/> Normal	<input type="checkbox"/> Functional
<input type="checkbox"/> -1639 G>A	<input type="checkbox"/> Carrier	<input type="checkbox"/> Deficient
<input type="checkbox"/> Other _____ (from 6 mutations)	<input type="checkbox"/> Double Carrier	<input type="checkbox"/> Resistant
<input type="checkbox"/> <i>Specimen did not meet LPH acceptability</i>		

Comments and recommendations: _____

Refer to the LPH website at www.genomas.net/LPH for additional clinical and scientific background information.

Test Report Date

Signed: _____
Gualberto Ruaño, M.D., Ph.D.
Laboratory Director

DISCLAIMERS

- Dosage recommendations obtained using regression (e.g. Sconce et al. **Blood** 106: 2329, 2005) are intended for use by a physician only as a guideline in conjunction with clinical presentation and other diagnostic data when making therapy decisions. A Patient's response to drug therapy depends on multiple non-genetic factors, including patient compliance with regimen, drug interactions, and diet.
- The *HILomet Warfarin* test, including DNA extraction and DNA typing of CYP2C9 and VKORC1 genes, was performed by the Laboratory of Personalized Health (LPH) under its license from the CT Department of Public Health (license CL-0644) and certification with the Centers for Medicare and Medicaid (ID# 07D1036625) under CLIA (Clinical Laboratory Improvement Amendments). *HILomet* tests have not been cleared or approved by the Food and Drug Administration (FDA). FDA approval or clearance is not required for the *HILomet* tests.